[Form 4] Magnera Corp Insider Trading Activity

Rhea-AI Filing Summary

Magnera Corp (MAGN) reported that director Mary Hall received a grant of 5,871 restricted stock units (RSUs) on 11/14/2025. These RSUs have an exercise price of $0 and are scheduled to vest in full on 11/14/2026, one year from the grant date. Following this grant, she beneficially owns 5,871 derivative securities in the form of RSUs, held directly.

The company explains that this award is a 2025 Prorated Director Award, intended to align the director equity schedule with the timing of the Annual Shareholder Meeting. The grant represents a prorated value of the Annual Director Award for the period between the 2024 RSU lapse reported on November 4, 2025 and the 2026 Annual Shareholder Meeting, when directors who are reelected are expected to receive a full 2026 Annual Director Award.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hall Mary Dean

(Last) (First) (Middle)

9335 HARRIS CORNERS PKWY

SUITE 300

(Street)

CHARLOTTE NC 28269

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Magnera Corp [ MAGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/14/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	11/14/2025		A		5,871(2)		11/14/2026(3)	11/14/2026	Common Stock, Par Value $.01	5,871	$0	5,871	D

Explanation of Responses:

1. Not applicable to this transaction. RSUs have no value until all restrictions lapse on the final vesting date.

2. To align the director equity schedule with the Annual Shareholders Meeting moving forward, this grant represents a prorated value of the Annual Director Award for the period between the 2024 RSU lapse reported on November 4, 2025 and the Annual Shareholder Meeting in 2026, at which time directors will be granted a full 2026 Annual Director Award upon their reelection.

3. This 2025 Prorated Director Award vests in full one year from the grant date.

	/s/ Laura A. Jones, attorney-in-fact for Mary Hall	11/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did Magnera Corp (MAGN) disclose for director Mary Hall?

Magnera Corp disclosed that director Mary Hall received a grant of 5,871 restricted stock units (RSUs) on 11/14/2025, reported as an acquisition of derivative securities on a Form 4.

How many Magnera Corp RSUs does Mary Hall own after this Form 4 transaction?

After the reported transaction, Mary Hall beneficially owns 5,871 derivative securities in the form of Magnera Corp RSUs, held in direct ownership.

When do Mary Hall's newly granted Magnera Corp RSUs vest?

The 5,871 Magnera Corp RSUs granted to Mary Hall on 11/14/2025 are scheduled to vest in full on 11/14/2026, one year from the grant date.

What is the exercise or conversion price of Mary Hall's Magnera Corp RSUs?

The reported Magnera Corp RSUs for Mary Hall have a conversion or exercise price of $0, reflecting that they are equity awards that convert into common stock upon vesting without additional cash payment.

Why is Mary Hall's Magnera Corp RSU grant described as a prorated director award?

The filing states that this grant is a 2025 Prorated Director Award to align the director equity schedule with the Annual Shareholder Meeting, covering the period between the 2024 RSU lapse reported on November 4, 2025 and the 2026 Annual Shareholder Meeting when directors will receive a full 2026 Annual Director Award upon reelection.

What role does Mary Hall hold at Magnera Corp according to this Form 4?

Mary Hall is identified as a Director of Magnera Corp, with the Form 4 indicating the relationship of the reporting person to the issuer as a director.